197079-25-7

Basic information

• Product Name: 3-Pyridinecarboxylicacid,6-methyl-,hydrazide(9CI)
• Synonyms: 3-Pyridinecarboxylicacid,6-methyl-,hydrazide(9CI);6-Methyl-3-pyridinecarboxylic acid hydrazide
• CAS NO: 197079-25-7
• Molecular Formula: C₇H₉N₃O
• Molecular Weight: 151.17
• Product Categories: AMIDE
• Mol File: 197079-25-7.mol
• Article Data: 11

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-Pyridinecarboxylicacid,6-methyl-,hydrazide(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Pyridinecarboxylicacid,6-methyl-,hydrazide(9CI)(197079-25-7)
• EPA Substance Registry System: 3-Pyridinecarboxylicacid,6-methyl-,hydrazide(9CI)(197079-25-7)

Safety Data

• Hazardous Substances Data: 197079-25-7(Hazardous Substances Data)

Usage

General Description

3-Pyridinecarboxylicacid,6-methyl-,hydrazide(9CI), also known as isonicotinic acid hydrazide, is a chemical compound with the molecular formula C7H9N3O. It is a derivative of isoniazid, an anti-tuberculosis medication, and is often used as a precursor in the synthesis of various pharmaceuticals and agrochemicals. Isonicotinic acid hydrazide is a white to off-white crystalline powder that is insoluble in water and is stable under normal temperature and pressure conditions. It is also known for its potential uses in the treatment of neurodegenerative disorders, such as Alzheimer's and Parkinson's disease, due to its neuroprotective properties. However, it is important to handle this chemical with caution, as it may be harmful if ingested, inhaled, or absorbed through the skin, and it can cause irritation to the respiratory system and skin.

Upstream product

• 21684-59-3 ethyl 6-methylnicotinate 
• 5470-70-2 Methyl 6-methylnicotinate 
• 104-90-5 5-ethyl-2-methyl-pyridine 

Downstream Products

• 64038-04-6 6-methyl-nicotinoyl azide 
• 1362066-99-6 C₁₆H₁₄BrN₃O₂S 
• 328541-93-1 C₁₄H₁₂BrN₃O 
• 1362067-00-2 C₁₆H₁₄FN₃O₂S 
• 328542-27-4 C₁₄H₁₂FN₃O 
• 1362066-97-4 C₁₆H₁₄N₄O₄S 
• 328542-51-4 C₁₇H₁₉N₃O₄ 
• 1362067-03-5 C₁₉H₂₁N₃O₅S 
• 1362067-02-4 C₂₀H₂₄N₄O₂S 
• 1362066-98-5 C₁₇H₁₇N₃O₃S 
• 294649-27-7 C₁₅H₁₅N₃O₂ 
• 1362067-01-3 C₁₈H₂₀N₄O₂S 
• 328542-01-4 C₁₆H₁₈N₄O 
• 1362066-96-3 C₁₆H₁₄N₄O₄S 

Relevant articles and documents

Synthesis, characterization and molecular docking studies of some new 1,3,4-oxadiazolines bearing 6-methylpyridine moiety for antimicrobial property

A new series of 3-acetyl-2-aryl-2H/methyl-5-[3-(6-methylpyridinyl)]-2,3- dihydro-[1,3,4]-oxadiazole derivatives were synthesized from 6-methyl nicotinate through a multistep reaction sequence. The structures of newly synthesized compounds were established on the basis of elemental analysis, IR, 1H NMR, 13C NMR and mass spectral data. Three dimensional structure of the compound 5f was further confirmed by single crystal X-ray analysis. All the synthesized compounds were screened for their antimicrobial activity and antioxidant activity. The final compounds were subjected to molecular docking studies for the inhibition of enzyme l-glutamine: D-fructose-6-phosphate amidotransferase [GlcN-6-P] (EC 2.6.1.16). The in silico molecular docking results are matching with the in vitro studies and they may be considered as good inhibitor of GlcN-6-P synthase.6-methylpyridine.

1, 2, 4 - Oxadiazole Nrf2 activator - tacrine split product as well as preparation method and application thereof

The invention discloses 1,oxadiazole Nrf2 activator - tacrine split products as well as a preparation method and application thereof. The invention relates to an acetylcholinesterase inhibitory activity. Nrf2 Activation activity, selective screening and Morris water maze test was carried out to evaluate the compound of general formula I, II, III for the treatment of's disease (in particular, severe's disease), found to have good in vitro, in vivo activity and extremely high selectivity, and can be used as a precursor substance for further development through selective inhibition of acetylcholinesterase and activation Nrf2.

Applications of 3-aryl-1,2,4-triazole-5(4H)-thione imide as NA inhibitors

The invention discloses 3-aryl-1,2,4-triazole-5(4H)-thione imide derivatives shown as a general formula I, pharmaceutically acceptable salts thereof, a preparing method of the derivatives, medicine compositions and applications of the derivatives and the salts in preparation of influenza virus neuraminidase inhibitors. The formula I is shown in the specification, wherein Z is selected from N or CH, X is selected from H, C1-C2 alkyl, C3-C4 direct-chain alkyl or branch-chain alkyl, Y1 is selected from hydrogen, C1-C2 alkyl, hydroxy, a methoxy group or an ethoxy group, Y2 is selected from hydrogen, C1-C2 alkyl, hydroxy, a methoxy group or an ethoxy group, Y3 is selected from hydrogen, C1-C2 alkyl, hydroxy, an ethoxy group, amino, methylamino, dimethylamino, acetamido, fluorine, chlorine, bromine or iodine, Y4 is selected from hydrogen, C1-C2 alkyl, hydroxy, a methoxy group or an ethoxy group, and Y5 is selected from hydrogen or C1-C2 alkyl.